Research Reports

Summary

Gyre Therapeutics disclosed its upcoming May 15, 2026 presentation in Shanghai featuring forward-looking statements on its pipeline—including CG923308, a CDK2/Cyclin E degrader for CCNE1-amplified solid tumors and CDK4/6 inhibitor-resistant breast cancer—and the strategic integration of Cullgen’s targeted protein degradation capabilities.

Key takeaways

CG923308 is a CRBN-dependent CDK2/Cyclin E degrader with DC50 <0.3–0.7 nM across CCNE1-amplified cancer cell lines, selectively degrading CDK2 and Cyclin E1 without affecting known IMiD neosubstrates.

The presentation highlights CG923308’s preclinical activity: induction of senescence, G1 arrest, and potent growth inhibition in CCNE1-amplified ovarian, gastric, and TNBC models, and in abemaciclib-resistant HR+/HER2- breast cancer.

Gyre and Cullgen intend to leverage China-based operations (Shanghai discovery, Beijing manufacturing/commercialization) for accelerated, cost-efficient development of degraders and DACs as next-generation therapeutics.

The combined entity’s pipeline spans fibrosis (ETUARY™, F351), inflammatory diseases (CG620953), and cancer, with CG923308 in IND-enabling studies and planned Phase 1a/1b trials in CCNE1-amplified solid tumors and CDK4/6i-resistant breast cancer.

Full analysis

This 8-K furnishes Exhibit 99.1—a May 2026 scientific presentation—disclosing Gyre’s strategic direction following its announced acquisition of Cullgen and highlighting preclinical progress on CG923308, a novel CDK2/Cyclin E degrader. The presentation emphasizes mechanistic rigor: CG923308 induces potent, CRBN- and proteasome-dependent degradation of CDK2 and Cyclin E1 across multiple CCNE1-amplified cancer lines, with no off-target degradation of canonical IMiD substrates. Its functional impact includes senescence induction and sustained growth inhibition in both solid tumor models and CDK4/6 inhibitor–resistant breast cancer, supporting clinical advancement into Phase 1a/1b trials. The disclosure also outlines the operational rationale for the Cullgen integration—leveraging established China infrastructure for discovery, validation, and development—to accelerate degrader and DAC programs. While the filing contains no financial results, earnings guidance, or definitive transaction terms, it materially updates investors on the scientific validity, therapeutic rationale, and development trajectory of Gyre’s lead oncology asset and its expanded platform strategy. As a Regulation FD disclosure under Item 7.01, the information is furnished—not filed—and carries explicit forward-looking statement disclaimers regarding clinical timing, regulatory outcomes, and development risks.